Research digest: new horizons in heart failure therapy

Publication date: November 2019Source: The Lancet Diabetes &Endocrinology, Volume 7, Issue 11Author(s): Naveed Sattar, David Preiss
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research

Related Links:

ConclusionsIn this observational analysis of T2D and ASCVD, baseline β-blocker use was not associated with risks for severe hypoglycemia yet also was not associated with CV risk reduction over 3 years of follow-up, supporting a randomized examination of chronic β-blocker therapy in this patient population. (TECOS number, NCT00790205).
Source: American Heart Journal - Category: Cardiology Source Type: research
In conclusion, high-dose NR induces the onset of WAT dysfunction, which may in part explain the deterioration of metabolic health. Towards a Rigorous Definition of Cellular Senescence The accumulation of lingering senescent cells is a significant cause of aging, disrupting tissue function and generating chronic inflammation throughout the body. Even while the first senolytic drugs capable of selectively destroying these cells already exist, and while a number of biotech companies are working on the productio...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
ConclusionsIn AF patients, there is underuse of GDT for non-AF comorbidities. The association between GDT use and outcomes was strongest in heart failure and obstructive sleep apnea patients where use of GDT was associated with lower mortality and less AF progression.
Source: American Heart Journal - Category: Cardiology Source Type: research
Authors: Chudek A, Owczarek AJ, Ficek J, Almgren-Rachtan A, Chudek J Abstract Background: Home blood pressure monitoring (HBPM) became a standard in the management of hypertension. However, there are few data concerning the utilisation of blood pressure (BP) monitors in daily clinical practice.Aim: The aim of this analysis was to show: (1) how frequently hypertensive patients are equipped with BP monitors, (2) how often they perform regular HBPM and running BP diaries, (3) what are the correlates of utilisation of BP monitors, in a large real-life cohort of hypertensives examined for the efficacy of antihypertensiv...
Source: Blood Pressure - Category: Hematology Tags: Blood Press Source Type: research
Recent data indicate that optimal cardiovascular (CV) risk management negates most of the increased CV risk associated with diabetes mellitus1. However there was a persistent increased risk of heart failure (HF). Recent studies showing the beneficial effect of SGLT2 inhibitors in reducing incident heart failure highlights the need for new ways of identifying those at highest risk of heart failure and personalizing therapeutic interventions to this group2. As the onset of HF is mediated by the development of a cardiomyopathy, the use of natriuretic peptide (NP) screening might highlight those at higher risk.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Source Type: research
This study enrolled consecutive 615 hospitalized patients with heart failure. We investigated the associations between circulating acetoacetate and clinical characteristics or prognosis in HF patients.ResultsWe divided the patients into two groups based on circulating acetoacetate levels (high group: acetoacetate ≥35 µmoL/L, n = 313; and low group: acetoacetate
Source: IJC Heart and Vasculature - Category: Cardiology Source Type: research
ConclusionsHF-exacerbating medication regimens are often continued or started following an HF hospitalization. These findings highlight an ongoing need to develop strategies to improve safe prescribing practices in this vulnerable population.Central Illustration
Source: JACC: Heart Failure - Category: Cardiology Source Type: research
Publication date: Available online 6 November 2019Source: JACC: Heart FailureAuthor(s): Milton PackerAbstractBoth obesity and type 2 diabetes are important risk factors for the development of heart failure with a preserved ejection fraction (HFpEF), and both disorders increase the risk of systemic thromboembolic events. Traditionally, the risk of stroke has been explained by the strong association of these disorders with atrial fibrillation (AF). However, adiposity and diabetes are risk factors for systemic thromboembolism, even in the absence of AF, because both can lead to the development of an inflammatory and fibrotic ...
Source: JACC: Heart Failure - Category: Cardiology Source Type: research
In patients with diabetes, where cardiovascular morbidity is highly prevalent, recent cardiovascular outcomes trials have identified therapies in the modern glucagon-like peptide 1 receptor agonist (GLP-1RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) classes that significantly reduce cardiovascular events. A number of drugs in both classes have demonstrated reductions in the risk of the composite outcome of major adverse cardiovascular events (myocardial infarction, stroke, and cardiovascular death). In addition, SGLT2i drugs have a substantial impact on hospitalization for heart failure. Because GLP-1RA and SGL...
Source: Cardiovascular Endocrinology - Category: Cardiology Tags: Review Articles Source Type: research
AbstractBackgroundBariatric surgery is proven to be the most effective strategy for management of obesity and its related comorbidities. However, in Canada, patients awaiting bariatric surgery can be subjected to prolonged wait times, thereby subjecting them to increased morbidity and mortality, as well as decreased psychosocial well-being.ObjectiveTo assess the factors associated with prolonged wait times for bariatric surgery within a publicly funded, provincial bariatric network.MethodsThis was a retrospective population-based study of all patients aged> 18 years who were referred for bariatric surgery from April 200...
Source: Obesity Surgery - Category: Surgery Source Type: research
More News: Cardiology | Diabetes | Endocrinology | Heart | Heart Failure